Search research articles
Contact Us
Filters
Showing results (111-120 of 124) with videos related to
Page
of 13
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Sarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
Lancet (London, England)
|
September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Sheena McCormack, David T Dunn, Monica Desai, et al.
Lancet (London, England)
|
July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
JMIR Research Protocols
|
April 20, 2016
A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics
Janey Sewell, Andrew Speakman, Andrew N Phillips, et al.
Cancer Research
|
October 23, 2025
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Alicia M Chenoweth, Anthony Cheung, Jitesh Chauhan, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial
Marcilio J Fumagalli, Anna Kaczynska, Marius Allombert, et al.
Lancet (London, England)
|
May 7, 2019
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Alison J Rodger, Valentina Cambiano, Tina Bruun, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy
Mohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Cell
|
May 28, 2026
A causal link between autoantibodies and neurological symptoms in long COVID
Keyla Santos Guedes de Sá, Julio Silva, Rafael Bayarri-Olmos, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 124) with videos related to
Sort By:
Page
of 13
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Sarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
Lancet (London, England)
|
September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Sheena McCormack, David T Dunn, Monica Desai, et al.
Lancet (London, England)
|
July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
JMIR Research Protocols
|
April 20, 2016
A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics
Janey Sewell, Andrew Speakman, Andrew N Phillips, et al.
Cancer Research
|
October 23, 2025
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Alicia M Chenoweth, Anthony Cheung, Jitesh Chauhan, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial
Marcilio J Fumagalli, Anna Kaczynska, Marius Allombert, et al.
Lancet (London, England)
|
May 7, 2019
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Alison J Rodger, Valentina Cambiano, Tina Bruun, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy
Mohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Cell
|
May 28, 2026
A causal link between autoantibodies and neurological symptoms in long COVID
Keyla Santos Guedes de Sá, Julio Silva, Rafael Bayarri-Olmos, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Page
of 13